CONMED Exits Gastroenterology Portfolio, Reaffirms 2025 Outlook with 80 Basis Points Margin Boost

CONMED plans to exit its gastroenterology portfolio to focus on core markets. The portfolio is expected to generate $90-95mln in revenue in 2025 with 45% gross margins. The exit will dilute EPS by $0.45-$0.55 in 2026 but lift consolidated gross margins by 80 basis points. Proceeds will be used for strategic investments, debt reduction, and share buybacks. The company reaffirmed its 2025 revenue guidance of $1.365bln-$1.372bln and adjusted EPS of $4.48-$4.53.